Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen by Pfizer
Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen by Pfizer True Acquisition Cost to Pfizer Estimated at Approximately $22 Million, Yet Icagen’s Pain Programs Are Estimated to Be Worth $100-$165 Million Pfizer Possesses Information Not Available to Other Potential Acquirers PR Newswire NEW YORK, Aug. 25, 2011 NEW YORK , Aug. 25, 2011 /PRNewswire/ — Merlin Nexus and New Leaf Venture Partners (NLV Partners) have contested the terms of Icagen’s (Nasdaq: ICGN) proposed acquisition by Pfizer Inc (NYSE: PFE) in a letter filed today with the SEC […]